# Per Olav Vandvik

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/per-olav-vandvik/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,344 |
| Field | Clinical practice guidelines implementation |
| h-index | 85 |
| i10-index | 221 |
| Last Known Institution | University of Oslo |
| OpenAlex ID | https://openalex.org/A5017952355 |
| ORCID iD | https://orcid.org/0000-0001-8958-2710 |
| Works | 357 |

## Researcher papers

Showing 12 of 14.

- [A living WHO guideline on drugs for covid-19 (2020-2023)](https://scholariq.org/papers/a-living-who-guideline-on-drugs-for-covid-19-2020-2023/)
- [Drug treatments for covid-19: living systematic review and network meta-analysis](https://scholariq.org/papers/drug-treatments-for-covid-19-living-systematic-review-and-network-meta-analysis/)
- [Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients](https://scholariq.org/papers/use-of-grade-for-assessment-of-evidence-about-prognosis-rating-confidence-in/)
- [GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines](https://scholariq.org/papers/grade-evidence-to-decision-etd-frameworks-a-systematic-and-transparent-approach-2/)
- [Guideline for opioid therapy and chronic noncancer pain](https://scholariq.org/papers/guideline-for-opioid-therapy-and-chronic-noncancer-pain/)
- [Opioids for Chronic Noncancer Pain](https://scholariq.org/papers/opioids-for-chronic-noncancer-pain/)
- [GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks](https://scholariq.org/papers/grade-guidelines-28-use-of-grade-for-the-assessment-of-evidence-about-prognostic/)
- [Credibility of claims of subgroup effects in randomised controlled trials: systematic review](https://scholariq.org/papers/credibility-of-claims-of-subgroup-effects-in-randomised-controlled-trials/)
- [Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials](https://scholariq.org/papers/benefits-and-harms-of-drug-treatment-for-type-2-diabetes-systematic-review-and/)
- [Retracted: Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials](https://scholariq.org/papers/retracted-pharmacotherapy-for-adults-with-overweight-and-obesity-a-systematic/)
- [Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies](https://scholariq.org/papers/incretin-treatment-and-risk-of-pancreatitis-in-patients-with-type-2-diabetes/)
- [Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies](https://scholariq.org/papers/dipeptidyl-peptidase-4-inhibitors-and-risk-of-heart-failure-in-type-2-diabetes/)

## Researcher topics

- [Clinical practice guidelines implementation](https://scholariq.org/topics/clinical-practice-guidelines-implementation/)
- [Meta-analysis and systematic reviews](https://scholariq.org/topics/meta-analysis-and-systematic-reviews/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Health Policy Implementation Science](https://scholariq.org/topics/health-policy-implementation-science/)

## Researcher university

- [University of Oslo](https://scholariq.org/institutions/university-of-oslo/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.